Stock of the Day

January 14, 2022

IQVIA (IQV)

$261.29
-$0.46 (-0.2%)
Market Cap: $43.08B

About IQVIA

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

IQVIA Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • IQVIA Holdings Inc. reported earnings per share (EPS) of $3.15 for the latest quarter, surpassing expectations, which indicates strong financial performance and potential for growth.
  • The company has a robust return on equity of 30.25%, suggesting effective management and the ability to generate profits from shareholders' investments.
  • With a net margin of 8.10%, IQVIA Holdings Inc. demonstrates efficiency in converting revenue into profit, which is attractive for investors looking for stable returns.
  • Recent revenue growth of 8.7% year-over-year highlights the company's ability to expand its market presence and increase sales, making it a potentially lucrative investment.
  • The current stock price is around $232, and the company has initiated a $2.00 billion share buyback plan, indicating that management believes the stock is undervalued, which could lead to price appreciation.

IQVIA Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • Insider selling has been observed, with significant shares sold recently, which may raise concerns about the confidence of those closest to the company in its future performance.
  • Despite strong earnings, the company operates in a highly competitive market, which could impact its ability to maintain growth and profitability in the long term.
  • High institutional ownership, at 89.62%, may lead to volatility in stock price as large investors can significantly influence market movements.
  • The company has set its FY 2026 EPS guidance at 12.800-13.000, which may be seen as conservative and could limit investor enthusiasm if growth expectations are not met.
  • Market conditions and regulatory changes in the healthcare sector could pose risks to IQVIA Holdings Inc.'s business model and financial stability.
← Previous Stock of the DayNext Stock of the Day →

Recent News